 |
市场调查报告书
商品编码
1684654
环孢菌素市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测Cyclosporine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球环孢菌素市场价值为 33 亿美元，预计 2025 年至 2034 年期间将以 14.5% 的复合年增长率强劲增长。随着越来越多的人接受挽救生命的移植手术，对环孢菌素控制免疫反应的需求正在迅速增加。
除了器官移植之外，类风湿性关节炎、牛皮癣和自体免疫性重症肌无力等自体免疫疾病的日益普及也对市场产生了很大影响。环孢菌素已被证明是治疗这些疾病的有效选择，从而推动了其在製药业的需求。随着发展中地区医疗保健服务的不断改善，越来越多的患者接受环孢素治疗，进一步加速了其市场的成长。全球对器官捐赠认识的提高和移植技术的不断进步也促进了环孢菌素的使用量的增加。
| 市场范围 | |
|---|---|
| 起始年份 | 2024 |
| 预测年份 | 2025-2034 |
| 起始值 | 33亿美元 |
| 预测值 | 127亿美元 |
| 复合年增长率 | 14.5％ |
随着先进免疫抑制疗法研发投资的预计激增，预计未来几年市场将迅速扩张。市场依适应症细分，包括移植排斥预防、自体免疫性重症肌无力、类风湿性关节炎、牛皮癣、干眼症等。 2024 年，移植排斥预防占最大的市场份额，价值 12 亿美元。这种优势是由于环孢菌素在预防器官排斥方面发挥的关键作用，特别是对于肾臟、肝臟和心臟移植患者。随着移植技术的进步和术后护理的发展，对有效预防性治疗的需求持续上升。
就剂型而言，环孢菌素有眼药水、溶液、乳膏、软膏和胶囊等形式。胶囊在 2024 年占据最大的市场份额，占整个市场的 31.8%。由于其易于使用且在长期治疗中有效，特别是对于自体免疫疾病和器官移植，因此成为首选形式。封装技术的进步提高了环孢菌素的生物利用度和稳定性，推动了该领域的进一步成长。
美国环孢菌素市场价值在 2024 年达到 11 亿美元，由于其先进的医疗保健系统、免疫抑制治疗的高采用率以及自体免疫疾病等慢性病和器官移植需求的广泛流行，该市场处于领先地位。知名产业参与者的存在，加上持续的创新和有利的报销政策，为环孢素市场的持续成长创造了肥沃的环境。
目录
第 1 章：方法论与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业衝击力
- 成长动力
- 自体免疫疾病盛行率不断上升
- 器官移植程序的成长
- 增加潜在临床候选药物
- 产业陷阱与挑战
- 不良副作用
- 成长动力
- 成长潜力分析
- 监管格局
- 管道分析
- 波特的分析
- PESTEL 分析
第四章：竞争格局
- 介绍
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 策略仪表板
第 5 章：市场估计与预测：按适应症，2021 年至 2034 年
- 主要趋势
- 移植排除预防
- 类风湿关节炎
- 牛皮癣
- 自体免疫性重症肌无力
- 干眼症
- 其他适应症
第 6 章：市场估计与预测：按剂型，2021 – 2034 年
- 主要趋势
- 胶囊
- 眼药水
- 解决方案
- 乳霜和软膏
第 7 章：市场估计与预测：按管理路线，2021 年至 2034 年
- 主要趋势
- 口服
- 主题
- 肠外
第 8 章：市场估计与预测：按配销通路，2021 年至 2034 年
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第 9 章：市场估计与预测：按地区，2021 年至 2034 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
第十章：公司简介
- Avet Pharmaceuticals
- AdvaCare Pharm
- AbbVie
- Apotex
- Cipla
- Dr. Reddy's Laboratories
- Novartis
- Santen Pharmaceutical
- Sun Pharmaceutical Industries
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries
- Viatris
The Global Cyclosporine Market, valued at USD 3.3 billion in 2024, is expected to experience robust growth at a CAGR of 14.5% from 2025 to 2034. This impressive expansion is mainly driven by the rising demand for organ transplantation procedures, which depend on immunosuppressive therapies to prevent organ rejection. As more people undergo life-saving transplants, the need for cyclosporine to manage immune responses is increasing rapidly.
In addition to organ transplants, the market is being significantly influenced by the growing prevalence of autoimmune disorders such as rheumatoid arthritis, psoriasis, and autoimmune myasthenia gravis. Cyclosporine has proven to be an effective treatment option for managing these conditions, boosting its demand in the pharmaceutical industry. As healthcare access continues to improve in developing regions, more patients are being treated with cyclosporine, further accelerating its market growth. The global push toward increasing awareness of organ donation and the continuous advancements in transplant technologies are also contributing to the increasing usage of cyclosporine.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $3.3 Billion |
| Forecast Value | $12.7 Billion |
| CAGR | 14.5% |
With a projected surge in R&D investments for advanced immunosuppressive therapies, the market is expected to expand rapidly in the coming years. The market is segmented by indication, including transplant rejection prophylaxis, autoimmune myasthenia gravis, rheumatoid arthritis, psoriasis, dry eye, and others. In 2024, transplant rejection prophylaxis held the largest share of the market, valued at USD 1.2 billion. This dominance is due to the critical role cyclosporine plays in preventing organ rejection, particularly in kidney, liver, and heart transplant patients. As transplant techniques improve and post-surgical care evolves, the demand for effective prophylactic treatments continues to rise.
When it comes to dosage forms, cyclosporine is available in eye drops, solutions, creams and ointments, and capsules. Capsules accounted for the largest market share in 2024, making up 31.8% of the total market. Their ease of use and effectiveness in long-term treatments, particularly for autoimmune diseases and organ transplants, make them the preferred form. Advances in encapsulation technologies have enhanced cyclosporine's bioavailability and stability, driving further growth in this segment.
The U.S. cyclosporine market, valued at USD 1.1 billion in 2024, stands as a leader due to its advanced healthcare system, high adoption rates of immunosuppressive treatments, and the widespread prevalence of chronic conditions like autoimmune disorders and the need for organ transplants. The presence of prominent industry players, coupled with continuous innovation and favorable reimbursement policies, creates a fertile environment for the sustained growth of the cyclosporine market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of autoimmune diseases
- 3.2.1.2 Growing organ transplantation procedures
- 3.2.1.3 Increase in potential clinical pipeline candidates
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Adverse side effects
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Transplant rejection prophylaxis
- 5.3 Rheumatoid arthritis
- 5.4 Psoriasis
- 5.5 Autoimmune myasthenia gravis
- 5.6 Dry eye
- 5.7 Other indications
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Capsule
- 6.3 Eye drops
- 6.4 Solutions
- 6.5 Creams and ointments
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Topical
- 7.4 Parenteral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 Avet Pharmaceuticals
- 10.2 AdvaCare Pharm
- 10.3 AbbVie
- 10.4 Apotex
- 10.5 Cipla
- 10.6 Dr. Reddy's Laboratories
- 10.7 Novartis
- 10.8 Santen Pharmaceutical
- 10.9 Sun Pharmaceutical Industries
- 10.10 Strides Pharma Science Limited
- 10.11 Teva Pharmaceutical Industries
- 10.12 Viatris
